Transcripta Bio (Series A)
Funding Details
Awarder
RSS - feeds.feedburner.com
Date Award
July 22, 2026
Vertical
Biotechnology
Funding URL
View Funding Page
Funding Amount
$24,000,000
Company Info
Traction
The company advances its pipeline toward human clinical trials with a portfolio spanning four programs across Myotonic Dystrophy, FSHD, ASD, and Huntington's Disease (HD).
Market
Neurological and neuromuscular diseases
Location
Palo Alto, California, USA
Coinvestors
Mayo Clinic, Omnimed, JAZZ Venture Partners, BlueYard Capital
Company Description

Transcripta Bio is an AI-powered drug discovery company focused on neurological and neuromuscular diseases, advancing IND-enabling studies across its portfolio and supporting clinical preparation in its Autism Spectrum Disorder (ASD) and Facioscapulohumeral Muscular Dystrophy (FSHD) programs.

Links
Website
Back to HomeBack to Biotechnology DealsView Funding Announcement